INFLUENCE OF VILDAGLIPTIN AND GLIQUIDONE COMBINATION ON P-GLYCOPROTEIN FUNCTIONAL ACTIVITY AND EXPRESSION ON THE BACKGROUND OF NORM AND IN EXPERIMENTAL ALLOXAN-INDUCED DIABETES MELLITUS TYPE 2

Abstract

In the in vivo study on rabbits investigated the effect of the vildagliptin and gliqui-done combination on the background of norm and experimental alloxan-induced diabetes mellitus (DM) type 2 on the P-glycoprotein (P-gp, ABCB1 protein) functional activity and its expression in the tissues of the jejunum, liver, kidney and the blood-brain barrier. Introduction of combination of vildagliptin at a dose of 5 mg/kg and gliquidone 10 mg/kg body weight on the background of norm for 14 days did not result in P-glycoprotein changes. On the 5-day of the cancellation of this combination observed inhibition of transporter protein functional activity without altering its expression. In the combination therapy of vildagliptin and gliquidone alloxan-induced diabetes type 2 showed complete recovery of P-glycoprotein functional activity and expression reduced on the pathology background. On the 5-day of treatment withdrawal again occurred inhibition of functional activity of the transporter protein and a decrease in its expression.

Keywords

P-glycoprotein / diabetes mellitus type 2 / vildagliptin / gliquidone

References

[1] Якушева Е.Н., Черных И.В., Щулькин А.В., Котлярова А.А., Никифоров А.А. Половые различия функциональной активности и экспрессии гликопротеина-Р у кроликов // Российский физиологический журнал им. И.М. Сеченова. 2014. Т. 100, № 8. C. 944-952.

[2] Якушева Е.Н., Черных И.В., Щулькин А.В., Попова Н.М. Гликопротеин-Р: структура, физиологическая роль и молекулярные механизмы модуляции функциональной активности // Успехи физиологических наук. 2014. Т. 45, № 4. С. 89-98.

[3] Якушева Е.Н., Щулькин А.В., Черных И.В., Титов Д.С. Функциональная активность гликопротеина-Р при экспериментальных манипуляциях // Российский медико-биологический вестник имени академика И.П. Павлова. 2014. № 2. С. 74-77.

[4] Дедов И.И., Мельниченко Г.А., ред. Клинические рекомендации. Алгоритм специализированной медицинской помощи больным сахарным диабетом М., 2015. Вып. 7. 112 с. doi: 10.14341/DM20151S1-112

[5] Миронов А.Н., ред. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012. 944 с.

[6] Shukla R., Anand K., Prabhu K.M., Murthy P.S. Hypoglycaemic effect of the water extract of Ficus bengalensis in alloxan recovered, mildly diabetic and severely diabetic rabbits // International Journal of Diabetes in Developing Countries. 1994. Vol. 14. P. 78-81.

[7] Burkey B.F., Li X., Bolognese L., Balkan B., Mone M., Russell M. et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats // Journal of Pharmacology and Experimental Therapeutics. 2005. Vol. 315, № 2. Р. 688-695. doi: 10.1124/jpet.105.087064

[8] Хабриев Р.У., ред. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.: Медицина, 2005. 832 с.

[9] de Gasparo M., Hostetter G., Desaulles P.A. Effect of gliquidone on insulin binding to rabbit erythrocytes // Journal of Endocrinology. 1983. Vol. 97, № 1. P. 97-103.

[10] Титов Д.С., Никифорова Л.В. Влияние ингибитора ДПП-4 - вилдаглиптина на функциональную активность гликопротеина-Р in vivo // Российский медико-биологический вестник имени академика И.П. Павлова. 2015. №. 3. C. 54-60.

[11] Varghese F., Bukhari A.B., Malhotra R., De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples // PloS one. 2014. Vol. 9, №. 5. e96801 p. doi: 10.1371/journal.pone.0096801

[12] Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations / U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2012. 75 p. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf

[13] Ceriello A., Sportiello L., Rafaniello C., Rossi F. DPP-4 inhibitors: pharmacological differences and their clinical implications // Expert opinion on drug safety. 2014. Vol. 13, № 1. P. 57-68. doi: 10.1517/14740338.2014.944862

[14] Usdin T.B., Mezey E., Button D.C., Brownstein M.J., Bonner T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain // Endocrinology. 1993. Vol. 133, № 6. P. 2861-2870. doi: 10.1210/endo.133.6.8243312

[15] Cheeseman C.I., Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport // American Journal of Physiology-Gastrointestinal and Liver Physiology. 1996. Vol. 271, № 3. P. G477-G482

RIGHTS & PERMISSIONS

Yakusheva E.N., Titov D.S., Nikiforov A.A.